ELISA Market (2025-2032)
The ELISA Market was valued at $20.49 billion in 2024. This market is expected to reach $32.69 billion by 2032 from an estimated $21.63 billion in 2025, at a CAGR of 6.1% during the forecast period 2025-2032 ELISA Market Size & Forecast The growth of the ELISA market is primarily driven by the high
- Published
- Aug 2024
- Pages
- 350
- Format
- PDF + Excel
- Report ID
- MR-1314
- Base year
- 2024
- 2024 · BASELINE
- $20.49B
- 2032
- $32.69B
- CAGR 2025–2032
- 6.1%
2024 baseline · 2025–2032 forecast at 6.1% CAGR · hover a bar for the value
Key highlights
By Type: The Indirect ELISA Segment to Dominate the Market in 2025
By Offering: The Kits & Assays Segment to Dominate the ELISA Market in 2025
By Technology: The Colorimetric ELISA Segment to Dominate the Market in 2025
By Application: The Diagnostic Applications Segment to Dominate the ELISA Market in 2025
By End User: The Diagnostic Laboratories Segment to Dominate the ELISA Market in 2025
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 350 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 6.1% |
| Estimated Market Size (Value) | $32.69 Billion by 2032 |
| Segments Covered | By Type · Direct ELISA · Indirect ELISA · Sandwich ELISA · Competitive ELISA · By Offering · Kits & Assays · Analyzers · By Mode · Fully Automated · Semi-automated · By Type · Optical Grating ELISA Analyzers · Optical Filter ELISA Analyzers · Software · By Technology · Chemiluminescence ELISA · Colorimetric ELISA · Fluorescence ELISA · By Application · Research Applications · Drug Discovery & Monitoring · Protein Quantification · Antibody Detection · Biomarker Discovery · Other Drug Discovery & Monitoring Applications · Vaccine Development · Diagnostic Applications · Infectious Diseases · Autoimmune Diseases · Oncology · Other Diagnostic Applications · Food Testing · Other Applications · (Note 1: Other drug discovery & monitoring applications include toxicology studies and quality control. · Note 2: Other diagnostic applications include allergen testing and pregnancy testing. · Note 3: Other applications include agricultural, environmental, veterinary, and forensic applications.) · By End User · Pharmaceutical & Biotechnology Companies · Diagnostic Laboratories · CDMOs & CROs · Academic & Research Institutes · Food Laboratories · Other End Users · (Note: Other end users include home healthcare, the agriculture industry, and the forensics industry.) |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa) |
| Key Companies Profiled | Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), Revvity Inc. (U.S.), QuidelOrtho Corporation (U.S.), Becton, Dickinson and Company (U.S.), Repligen Corporation (U.S.), BioLegend (U.S.), and Bio-Techne Corporation (U.S.) |
Report overview
Segments covered: type, direct elisa, indirect elisa, sandwich elisa, competitive elisa, offering, kits & assay, analyzer, mode, fully automated, semi-automated, optical grating elisa analyzer, optical filter elisa analyzer, software, technology, chemiluminescence elisa, colorimetric elisa, fluorescence elisa, application, research application, drug discovery & monitoring, protein quantification, antibody detection, biomarker discovery, other drug discovery & monitoring application, vaccine development, diagnostic application, infectious disease, autoimmune disease, oncology, other diagnostic application, food testing, other application, pregnancy testing., environmental, veterinary, forensic applications.), end user, pharmaceutical & biotechnology company, diagnostic laboratory, cdmos & cro, academic & research institute, food laboratory, other end user. Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The growth of the ELISA market is primarily driven by the high burden of chronic & infectious diseases, the increasing use of ELISA in clinical applications, advancements in ELISA, and the growing use of ELISA in the food industry. Furthermore, growing research activities in developing countries, increasing R&D for biomarker detection, and the growing focus on vaccine development are expected to offer growth opportunities for market stakeholders.
Report infographic
Market dynamics
5 factors across 3 forcesHigh Burden of Chronic & Infectious Diseases
ELISA is performed to detect or screen patients for diseases such as cancer, HIV, and autoimmune diseases. The rising prevalence of these diseases drives the utilization of ELISA kits. According to the World Health Organization (WHO) report published in July 2024, nearly 39 million people had HIV as of 2022.
ELISA uses antibodies that are specific and sensitive to target antigens. It can detect lower concentrations of biomarkers. In cancer detection, ELISA kits detect biomarkers such as Alpha-fetoprotein (AFP) and β-2microglobulin (B2M). ELISA is easier to perform and provides results faster compared to other tests. According to GLOBOCAN, the number of new cancer cases is expected to rise by 63.4% between 2022 and 2045. Thus, rising cancer incidence and the high preference for ELISA tests in cancer detection and diagnosis drive the growth of this market.
Advancements in ELISA
ELISA is used to detect and measure antigens in biological samples. In recent years, key players have been focused on advancing ELISA. The integration of nanomaterials in ELISA is one such advancement that has improved sensitivity, enhanced overall performance, and helped in the detection of trace amounts of proteins or biomarkers. Nanomaterials such as white Fe-based Coordination Polymer Nanozymes (FCPN), Multiwalled Carbon Nanotubes (MWCNTs), and Metallic Nanoparticles (NP) help in hassle-free enzyme loading.
Aptamers produced through chemical synthesis are now replacing antibodies in ELISA procedures. Aptamers can be modified as required and are cheaper to produce. Also, aptamers can be synthesized against a wide range of target molecules; hence, ELISA tests can be used for detecting many chronic & infectious diseases. These advancements have enabled more accurate and faster results, easy processing, and cost and time savings.
Table of contents
13 chapters · 130 sections · 350 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Type | Indirect ELISA | — |
| By Offering | Kits & Assays | — |
| By Technology | Colorimetric ELISA | — |
| By Application | Diagnostic Applications | — |
| By End User | Diagnostic Laboratories | — |
By Type
- The Indirect ELISA Segment to Dominate the Market in 2025
- The indirect ELISA segment is expected to account for the largest share of 43.5% of the ELISA market.
- Indirect ELISA is a detection type where a primary antigen-specific antibody is recognized by a secondary conjugated antibody.
- Indirect ELISA is highly sensitive and flexible, which helps in binding more than one labeled secondary antibody.
- Indirect ELISA uses fewer labeled antibodies and is used to detect total antibody concentrations in biological samples.
- Thus, the high sensitivity, flexibility, and cost-effectiveness of indirect ELISA contribute to the segment’s large market share.
By Offering
- The Kits & Assays Segment to Dominate the ELISA Market in 2025
- The kits & assays segment is expected to account for the largest share of 85.2% of the ELISA market.
- ELISA kits are commonly used for disease diagnosis, pregnancy testing, cancer detection, vaccine development, and food allergen testing.
- The rising prevalence of diseases, coupled with growing awareness regarding early disease diagnosis, is contributing to the segment’s large market share.
By Technology
- The colorimetric ELISA segment is expected to account for the largest share of the ELISA market.
- Colorimetric ELISA uses colored reaction products to produce results.
- It uses labeled enzymes such as peroxidase or phosphatase for testing.
- Colorimetric ELISA is used for various types of samples, making it ideal for research applications.
- Colorimetric ELISA is non-destructive, and the samples can be used for further analysis.
- These factors support the segment’s large market share.
By Application
- The diagnostic applications segment is expected to account for the largest share of the ELISA market.
- Diagnostic applications are further subsegmented into infectious diseases, autoimmune diseases, oncology, and other diagnostic applications.
- The increasing prevalence of cancer, autoimmune diseases, and infectious diseases is driving the utilization of ELISA kits in diagnostic applications.
- According to the National Institute of Environmental Health Sciences (NIEHS), 50 million people in the U.S. have autoimmune diseases.
- Thus, the high prevalence of target diseases, coupled with the benefits of ELISA, such as high sensitivity, accuracy, and reliability, supports the segment’s large share.
By End User
- The diagnostic laboratories segment is expected to account for the largest share of the ELISA market.
- The segment’s large share is attributed to the high prevalence of infectious and chronic diseases, the reliable test results provided by diagnostic laboratories, and the expansion of diagnostic laboratories.
- Diagnostic laboratories perform various medical tests that help identify and diagnose medical conditions.
- Diagnostic laboratories are well-equipped with advanced technological solutions and, therefore, are able to process more samples quicker.
- Thus, the rising burden of diseases and diagnostic laboratories’ high preference for ELISA tests contribute to the segment’s large share.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 37.7% of the ELISA market. The region’s large share is attributed to pharmaceutical companies’ high focus on R&D, supportive government initiatives, and the presence of large pharmaceutical players in the region. There is also an increased focus on food testing due to the increasing number of food adulteration cases in the region. Key players in North America are also undertaking strategic initiatives to increase food testing capacities in the region. For instance, in June 2025, Spectacular Labs Inc. (U.S.) collaborated with the Canadian Centre for Meat Innovation & Technology to improve food safety testing. Similarly, in June 2024, Bureau Veritas (France) opened its fourth food laboratory in the U.S. in Chesterfield, Missouri. The laboratory offers rapid and conventional microbiology testing for food and agricultural commodities. Such developments are expected to drive the demand for ELISA kits for food testing, supporting the growth of this regional market. North America to Dominate the ELISA Market in 2025
Asia-Pacific
Fastest growthHowever, Asia-Pacific is slated to register the highest growth rate of 7.1% during the forecast period. The increasing number of healthcare facilities, diagnostic laboratories, and food testing laboratories in Asia-Pacific are driving the demand for ELISA in the region. Additionally, government initiatives for veterinary disease testing are driving the ELISA market in the region. Countries’ growing focus on improving human and animal healthcare, increasing investments in drug discovery, growth in diagnostic testing, and the growing focus on vaccination in Asia-Pacific are driving the demand for ELISA in the region. For instance, in May 2025, the Government of Australia started its vaccination drive for Influenza and released the list of available vaccines (Source: Commonwealth of Australia).
Competitive landscape
- February 2025
Gold Standard Diagnostics. (U.S.) launched Celer AFLA HS, an ELISA test kit for total aflatoxins detection in agricultural products such as maize and corn germ.
- January 2025
Rockland Immunochemicals, Inc. (U.S.) launched the AccuSignal Nuclease ELISA Kit for the detection of Serratia marcescens endonuclease & turbonuclease used in the manufacturing of biological therapeutics, gene therapies, and vaccines, among others.
- November 2024
F. Hoffmann-La Roche AG (Switzerland) launched the Elecsys HBeAg quant immunoassay to assess both the presence and quantity of hepatitis B antigen in biological samples.
- Merck KGaA · Germany
- Bio-Rad Laboratories Inc. (U.S.)
- F. Hoffmann-La Roche AG · Switzerland
- Danaher Corporation (U.S.)
- QIAGEN N.V. · Netherlands
- Agilent Technologies, Inc. (U.S.)
- Abbott Laboratories (U.S.)
- Revvity Inc. (U.S.)
- QuidelOrtho Corporation (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Repligen Corporation (U.S.)
- BioLegend (U.S.)
- Bio-Techne Corporation (U.S.)
Frequently asked questions
This report includes qualitative and quantitative analyses of the ELISA market based on type, offering, technology, application, end user, and geography. The report also provides insights on factors impacting market growth, along with a regulatory analysis, a pricing analysis, and Porter’s Five Forces analysis for the ELISA market.
Cite this report
Meticulous Research. (2024). ELISA Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-1314). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/elisa-market-5997